Skip to main content

Table 1 Pap smear findings, socio-demographic and behavioral characteristics of lupus patients and control subjects #

From: Antagonist-mediated down-regulation of toll-like receptors increases the prevalence of human papillomavirus infection in systemic lupus erythematosus

 

SLE patients

Control subjects

 

Group 1

(HPV-positive)

(n= 15)

Group 2

(HPV-negative)

(n= 31)

Group 3

(HPV-positive)

(n= 7)

Group 4

(HPV-negative)

(n= 22)

Pap smear findings

    

   Cytological abnormality *

8 (53)

1 (3) †††

5 (71)

3 (14) ‡‡

Demographic & social characteristics

    

   Age at study, mean ± S.D. (range), year

45 ± 10 (28 to 58)

47 ± 10 (30 to 63)

41 ± 10 (31 to 59)

44 ± 11 (25 to 62)

   Menopause

7 (47)

17 (55)

2 (29)

4 (18) §§

   Married

9 (60)

24 (77)

7 (100)

17 (77)

   Low education level (high school or lower)

12 (80)

25 (81)

7 (100)

15 (68)

   Monthly family income ≤ HK$ 10,000

6 (40)

9 (29)

1 (14)

6 (27)

   Alcohol

0 (0)

3 (10)

1 (14)

1 (5)

   Current smoker

0 (0)

3 (10)

1 (14)

1 (5)

   Employment

7 (47)

11 (35)

2 (29)

18 (82) ‡‡, §§

Reproductive and gynecologic characteristics

    

   First intercourse at young age (≤ 17 years)

2 (13)

4 (13)

1 (14)

2 (9)

   Multiple sexual partners (≥ 3)

3 (20)

2 (6)

4 (57)

1 (5) ‡‡

   History of sexually transmitted disease

1 (7)

0 (0)

0 (0)

0 (0)

   Oral contraceptives

2 (13)

3 (10)

1 (14)

2 (9)

   Condom use by male partner

6 (40)

11 (35)

3 (43)

11 (50)

   Current vaginal discharge

0 (0)

2 (6)

0 (0)

1 (5)

   Bleeding after intercourse

0 (0)

2 (6)

0 (0)

2 (9)

  1. # Values are the number (percentage) unless otherwise indicated. * Refers to atypical squamous cells of undetermined significance or squamous intraepithelial lesions. HPV = human papillomavirus; SLE = systemic lupus erythematosus; Group 1 = SLE with positive HPV DNA; Group 2 = SLE with negative HPV DNA; Group 3 = Control subjects with positive HPV DNA; Group 4 = Healthy controls with negative HPV DNA; ††† P <0.001, comparing between SLE patients with and without HPV infection. ‡‡ P <0.01, comparing between control subjects with and without HPV infection. §§ P < 0.01, comparing between SLE and control subjects without HPV infection